Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

## **Press Release**



## **Change in Corporate Officer's Responsibilities**

**TOKYO**, **June 27**, **2025** - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) announced the following change in corporate officer's responsibilities effective on July 1, 2025.

1. Change in Corporate Officer's Responsibilities

Change in Corporate Chicer of Neoponoisimiles	
	[New Responsibilities]
Tomohito Nagao	Corporate Officer,
	In Charge of Audit and Legal Affairs & Regulatory Compliance,
	Audit Department Director
	(Corporate Officer, Director of Information service Supervisory Unit of ASKA
	Pharmaceutical Co., Ltd.)
	[Current Responsibilities]
	Corporate Officer,
	In Charge of Audit and Legal Affairs & Regulatory Compliance
	(Corporate Officer, Director of Information service Supervisory Unit of ASKA
	Pharmaceutical Co., Ltd.)

## **Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd. Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp